2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
This guideline cites 9 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2017
- Source
- Al-Khatib SM, Stevenson WG, et al. Circulation. 2018;138(13):e272–e391.doi 10.1161/CIR.0000000000000549
The US guideline on ventricular arrhythmias appeared a year after DANISH and read that trial very differently from the Europeans: it keeps the primary-prevention ICD at Class 1 for symptomatic heart failure with LVEF ≤35% on optimal therapy without distinguishing ischaemic from non-ischaemic aetiology, whereas the ESC 2022 guideline downgraded non-ischaemic dilated cardiomyopathy to Class IIa on the same evidence. That single divergence still explains most differences in ICD implantation rates between the two regions. Beyond devices, the guideline stresses that the therapy which prevents most sudden deaths is guideline-directed medical heart-failure therapy, and it covers catheter ablation of ventricular tachycardia and the disease-specific channelopathy pathways. The register's device and drug trials are grouped below.
Primary-prevention ICD (Class 1 regardless of aetiology)3
- 2016DANISHCardiology · Arrhythmia · ICDIn 1,116 patients with non-ischaemic heart failure (EF ≤ 35 %), a prophylactic defibrillator did not reduce all-cause mortality compared with usual care.HR 0.87Read →
- 2005SCD-HeFT CoreCardiology · Arrhythmia · ICDIn 2,521 patients with heart failure (NYHA II–III, EF ≤ 35 %), an implantable defibrillator reduced all-cause mortality compared with placebo or amiodarone.Read →
- 2002MADIT-II CoreCardiology · Arrhythmia · ICDIn 1,232 patients with prior MI and an ejection fraction ≤ 30 %, a prophylactic implantable defibrillator reduced all-cause mortality compared with conventional therapy.HR 0.69Read →
Medical therapy that reduces sudden death3
- 2014PARADIGM-HF CoreCardiology · HF · ARNIIn 8,442 patients with HFrEF (EF ≤ 0.40), sacubitril/valsartan reduced CV death or hospitalisation for HF compared with enalapril.HR 0.8Read →
- 1999RALES CoreCardiology · HF · MRAIn 1,663 patients with severe HFrEF on ACEi, spironolactone 25 mg reduced all-cause mortality compared with placebo.RR 0.7095% CI 0.60-0.82Read →
- 1999MERIT-HF CoreCardiology · HF · Beta-blockadeIn 3,991 patients with HFrEF (EF ≤ 0.40, NYHA II–IV), metoprolol CR/XL reduced all-cause mortality compared with placebo.Read →
Cardiac resynchronisation therapy3
- 2009MADIT-CRTCardiology · Arrhythmia · CRTIn 1,820 patients with mild heart failure (NYHA I–II) and a wide QRS, adding resynchronisation to a defibrillator reduced death or heart-failure events compared with a defibrillator alone.HR 0.66Read →
- 2005CARE-HF CoreCardiology · Arrhythmia · CRTIn 813 patients with heart failure and a wide QRS, cardiac resynchronisation therapy reduced death or unplanned cardiovascular hospitalisation compared with medical therapy.39% vs 55%Read →
- 2004COMPANIONCardiology · Arrhythmia · CRTIn 1,520 patients with NYHA III-IV heart failure and QRS ≥ 120 ms, cardiac resynchronisation therapy (with or without a defibrillator) reduced all-cause death or hospitalisation compared with optimal medical therapy alone.Read →
Published since the guideline1
- 2020PRAETORIANCardiology · Arrhythmia · ICDIn 849 patients needing a defibrillator but no pacing, a subcutaneous ICD was non-inferior to a transvenous ICD for device complications and inappropriate shocks.HR 0.9995% CI 0.71-1.39Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 1997AVID
ICD vs. antiarrhythmic drugs for secondary prevention.
- 1996MADIT
First trial establishing prophylactic ICD benefit post-MI.
- 1999MUSTT
Electrophysiologically guided therapy in coronary disease with non-sustained VT.
- 2004DINAMIT
No benefit of an early ICD immediately after myocardial infarction.
- 2016VANISH
Catheter ablation vs. escalated antiarrhythmic drugs for recurrent VT.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.